Kang; Chang-Yuil

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kang; Chang-Yuil.The latest application filed is for "method for preparing antigen-specific cytotoxic t-cells by using activated b-cells and use thereof".

Company Profile

2.14.11

Kang; Chang-Yuil - Seoul KR
- Seoul KR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Method for preparing antigen-specific cytotoxic T-cells by using activated B-cells and use thereof Grant 10,443,040 - Kang , et al. Oc	2019-10-15
Composition for preventing, improving, or treating immune diseases comprising natural extracts as active ingredients Grant 10,016,475 - Shon , et al. July 10, 2	2018-07-10
Method For Preparing Antigen-specific Cytotoxic T-cells By Using Activated B-cells And Use Thereof App 20180023054 - KANG; Hyoung Jin ; et al.	2018-01-25
Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen Grant 9,518,126 - Kang , et al. December 13, 2	2016-12-13
Composition For Preventing, Improving, Or Treating Immune Diseases Comprising Natural Extracts As Active Ingredients App 20150118266 - Shon; Dong-Hwa ; et al.	2015-04-30
.alpha.-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient Grant 8,883,746 - Kang , et al. November 11, 2	2014-11-11
Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibody Grant 08617546 -	2013-12-31
Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibody Grant 8,617,546 - Kang , et al. December 31, 2	2013-12-31
Her-2/neu DNA vaccine having anti-cancer activity Grant 8,445,268 - Lee , et al. May 21, 2	2013-05-21
Anticancer Agent Comprising Anti-pd-1 Antibody Or Anti-pd-l1 Antibody App 20120237522 - KANG; Chang Yuil ; et al.	2012-09-20
B cell-based vaccine loaded with the ligand of natural killer T cell and antigen Grant 8,003,093 - Kang , et al. August 23, 2	2011-08-23
Her-2/neu DNA Vaccine Having Anti-Cancer Activity App 20100210714 - LEE; Joon Youb ; et al.	2010-08-19
Alpha-galactosylceramide Derivatives, Pharmaceutically Acceptable Salts Thereof, Preparation Method And Pharmaceutical Composition For The Immune Adjuvant Containing The Same As An Active Ingredient App 20100104590 - Kang; Chang-Yuil ; et al.	2010-04-29
Anticancer Agent Comprising Anti-pd-1 Antibody Or Anti-pd-l1 Antibody App 20100086550 - Kang; Chang Yuil ; et al.	2010-04-08
B Cell-based Vaccine Loaded With The Ligand Of Natural Killer T Cell And Antigen App 20100028380 - Kang; Chang-Yuil ; et al.	2010-02-04
Vaccine Comprising Monocyte Or Immature Myeloid Cells (imc) Which Were Loaded With The Ligand Of Natural Killer T Cell And Antigen App 20090285851 - Kang; Chang-Yuil ; et al.	2009-11-19
Vaccine Composition Comprising Alpha-Galactosylceramide as an Adjuvant For Intranasal Administration App 20080317769 - Kang; Chang-Yuil ; et al.	2008-12-25
Her-2 neu dna vaccine having anti-cancer activity App 20060074038 - Lee; Joon Youb ; et al.	2006-04-06
Isoxazoline derivative and a process for the preparation thereof Grant 6,747,050 - Kim , et al. June 8, 2	2004-06-08
Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies App 20030096976 - Hong, Hyo Jeong ; et al.	2003-05-22
Humanized antibody specific for human 4-1BB Grant 6,458,934 - Hong , et al. October 1, 2	2002-10-01
Monoclonal antibody specific for human 4-1BB and cell line producing same Grant 5,928,893 - Kang , et al. July 27, 1	1999-07-27

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.